Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT06331455	Phase II	Durvalumab	Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)	Recruiting	CAN	0
NCT03430063	Phase II	Cemiplimab + Ipilimumab Cemiplimab	A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer	Terminated	USA \| POL \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT02447003	Phase II	Pembrolizumab	Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)	Completed		0
NCT06234397	Phase I	BH3120	Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors	Recruiting	USA	1
NCT05063552	Phase II	Bevacizumab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Bevacizumab + Carboplatin + Docetaxel Cetuximab + Cisplatin + Docetaxel Atezolizumab + Bevacizumab	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	Recruiting	USA	0
NCT05909904	Phase II	LBL-007 + Tislelizumab Tislelizumab BGB-A425 + Tislelizumab BGB-A425 + LBL-007 + Tislelizumab	Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma	Active, not recruiting	USA \| TUR \| ITA \| GBR \| FRA \| ESP \| CAN \| AUS	6
NCT04177108	Phase III	Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel	A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.	Completed	USA \| TUR \| ROU \| POL \| NZL \| ITA \| ISR \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	15
NCT06340711	Phase II	OBP-301 + Pembrolizumab	Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	Recruiting	USA	0
NCT03829332	Phase III	Pembrolizumab Lenvatinib + Pembrolizumab	Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)	Completed	USA \| TUR \| POL \| ITA \| ISR \| HUN \| FRA \| EST \| CAN \| AUS	9
NCT04448886	Phase II	Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy	Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC	Active, not recruiting	USA	0
NCT06557889	Phase II	Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab	Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE)	Recruiting	FRA	0
NCT06357858	Phase I	Decitabine and Cedazuridine + Nivolumab	ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck	Withdrawn	USA	0
NCT03293680	Phase II	Pembrolizumab	Pembrolizumab in Elderly Patients With Advanced Lung Cancer	Completed	ESP	0
NCT05472506	Phase I	KYN-175 + Nivolumab	Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer	Withdrawn	USA	0
NCT05577182	Phase I	INCA32459	Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies	Active, not recruiting	USA \| ITA \| ESP \| BEL	0
NCT03854474	Phase Ib/II	Pembrolizumab + Tazemetostat	Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	Active, not recruiting	USA \| CAN	0
NCT04513925	Phase III	Atezolizumab + Tiragolumab Durvalumab	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)	Active, not recruiting	USA \| TUR \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT04633278	Phase II	Pembrolizumab + Vidutolimod	CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Terminated	USA	0
NCT04624113	Phase Ib/II	Pembrolizumab + Tazemetostat	Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	Terminated	USA	0
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Recruiting	USA \| NLD \| GBR \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	9
NCT02589717	FDA approved	Atezolizumab	An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy	Approved for marketing	USA	0
NCT04799249	Phase III	Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)	Completed	USA \| POL \| FRA \| ESP \| BGR \| AUS	5
NCT04007744	Phase I	Pembrolizumab + Sonidegib	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT04690855	Phase II	Atezolizumab + Talazoparib	A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)	Terminated	USA	0
NCT05212922	Phase II	Toripalimab-tpzi + YH001	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)	Withdrawn	AUT \| AUS	3
NCT02450331	Phase III	Atezolizumab	A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010)	Terminated	USA \| TUR \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL \| AUS	7
NCT03326752	Phase I	DV281	Phase 1b Dose Escalation and Dose Expansion Trial	Completed	USA	0
NCT04524689	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701	Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)	Terminated	USA \| ISR \| HUN \| FRA \| ESP \| CZE \| BRA	1
NCT05382286	Phase III	Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT04148911	Phase III	Atezolizumab + Nab-paclitaxel	A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)	Completed	SVN \| ROU \| POL \| ITA \| HUN \| FRA \| ESP \| CZE \| ARG	4
NCT04302025	Phase II	Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib	A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT04166487	Phase II	Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium	Plasma-Adapted First-Line Pembro in NSCLC	Active, not recruiting	USA	0
NCT05799144	Phase II	pBI-11 vaccine + Pembrolizumab	pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS>=1, hrHPV+ Oropharyngeal Cancer	Recruiting	USA	0
NCT04612751	Phase I	Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Recruiting	USA \| TUR \| POL \| ITA \| FRA \| ESP \| BEL	3
NCT05029999	Phase I	CDX-1140 + CDX-301 + Pegylated liposomal doxorubicin	CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer	Recruiting	USA	0
NCT06082167	Phase II	Pembrolizumab + XL092 Pembrolizumab	Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)	Recruiting	USA \| SVK \| ROU \| POL \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| CZE \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	7
NCT03546426	Phase I	Aldesleukin + Pembrolizumab	Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)	Active, not recruiting	ITA	0
NCT06589804	Phase III	Cetuximab + Pembrolizumab Pembrolizumab	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment	Recruiting	USA	0
NCT06636734	Phase II	Lovastatin + Pembrolizumab	Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial	Not yet recruiting	USA	0
NCT04671667	Phase II	Cisplatin Pembrolizumab Carboplatin	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	Recruiting	USA	0
NCT05653661	Phase I	AP-160	Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors	Withdrawn	USA	0
NCT06014502	Phase I	IMGS-001	Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Recruiting	USA	0
NCT04453046	Phase I	Pembrolizumab	Hemopurifier Plus Pembrolizumab in Head and Neck Cancer	Terminated	USA	0
NCT05141357	Phase II	Chidamide + Pembrolizumab	A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000)	Terminated	USA	0
NCT04130516	Phase Ib/II	LNS8801 LNS8801 + Pembrolizumab	Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab	Recruiting	USA	0
NCT04940637	Phase II	Dostarlimab-gxly + Niraparib	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)	Recruiting	ITA	0
NCT05077709	Phase II	IO102-IO103 + Pembrolizumab	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	USA \| GBR \| ESP	0
NCT04584112	Phase I	Atezolizumab + Cyclophosphamide + Doxorubicin + Pegfilgrastim + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Sargramostim + Tiragolumab Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Tiragolumab	A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer	Completed	USA \| ESP \| DEU \| BRA \| AUS	3
NCT04198766	Phase I	INBRX-106 INBRX-106 + Pembrolizumab	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	Recruiting	USA	0
NCT03348904	Phase III	Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium	Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer	Terminated	USA	0
NCT06558799	Phase II	Pembrolizumab	LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) (LUNAR-4)	Recruiting	POL \| NLD \| ITA \| ESP \| AUT	0
NCT04665843	Phase II	Atezolizumab + Tiragolumab Atezolizumab	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09)	Active, not recruiting	USA \| POL \| NZL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| CZE	3
NCT06690840	Phase II	Atezolizumab + Cyclophosphamide + Vinorelbine	Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients (AZALEA)	Not yet recruiting	ITA	0
NCT05132803	Phase I	TA-CIN	TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers	Withdrawn	USA	0
NCT05287113	Phase II	INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab	Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Active, not recruiting	USA \| POL \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BEL	4
NCT04740918	Phase III	Ado-trastuzumab emtansine + Atezolizumab Ado-trastuzumab emtansine	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)	Terminated	USA \| TUR \| SVN \| POL \| NOR \| ITA \| HRV \| GRC \| GBR \| FRA \| FIN \| ESP \| CAN \| BRA \| AUS	6
NCT05075122	Phase II	Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab	Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS)	Recruiting	DEU	0
NCT05340309	Phase II	Atezolizumab + rHuPH20	Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer	Recruiting	USA	0
NCT04305795	Phase Ib/II	ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Active, not recruiting	USA	0
NCT06046482	Phase II	Cetuximab + Docetaxel + Hu5F9-G4 Cetuximab + Hu5F9-G4 + Pembrolizumab	Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma	Terminated	USA	0
NCT04521621	Phase Ib/II	Coxsackievirus A21 + Pembrolizumab	A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)	Terminated	USA \| POL \| NOR \| ITA \| ISR \| HUN \| FRA \| ESP \| DEU \| CAN	4
NCT04892472	Phase II	Pembrolizumab	EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)	Recruiting	USA	0
NCT05544929	Phase I	KFA115 KFA115 + Pembrolizumab	A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers	Recruiting	USA \| ITA \| ESP \| DEU \| CAN	4
NCT04243616	Phase II	Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel	Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer	Recruiting	USA	0
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	4
NCT04238988	Phase II	Carboplatin + Paclitaxel + Pembrolizumab	Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3)	Unknown status	ITA	0
NCT06295731	Phase II	INBRX-106 + Pembrolizumab Pembrolizumab	INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>=20 HNSCC (HexAgon-HN)	Recruiting	USA	0
NCT04881045	Phase I	PF-07257876	Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.	Completed	USA \| ESP	0
NCT05661578	Phase II	Atezolizumab + Tiragolumab	A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)	Recruiting	USA \| TUR \| HRV \| GRC \| ESP \| CYP \| CAN	4
NCT02879994	Phase II	Pembrolizumab	Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer	Completed	USA	0
NCT02409355	Phase III	Carboplatin Cisplatin Gemcitabine Atezolizumab	A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer	Terminated	USA \| ROU \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE	3
NCT06267001	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)	Active, not recruiting	USA \| TUR \| SVK \| POL \| ITA \| FRA \| ESP \| BRA \| AUS \| ARG	6
NCT04895358	Phase III	Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUT \| AUS \| ARG	11
NCT02041533	Phase III	Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)	Completed	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	4
NCT06052839	Phase II	Carboplatin + Paclitaxel + Pembrolizumab	Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC	Recruiting	USA	0
NCT03606967	Phase II	Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine Nab-paclitaxel Carboplatin + Gemcitabine Durvalumab + Nab-paclitaxel + Tremelimumab	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	Recruiting	USA	0
NCT03735121	Phase III	Atezolizumab + rHuPH20 Atezolizumab	A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Active, not recruiting	TUR \| POL \| NZL \| LVA \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| BRA \| ARG	11
NCT04165083	Phase II	MK-4830 + Pembrolizumab	KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)	Active, not recruiting	USA \| POL \| ITA \| ISR \| HUN \| ESP	1
NCT02576574	Phase III	Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin	Avelumab in First-line NSCLC (JAVELIN Lung 100)	Completed	USA \| TUR \| SVK \| ROU \| POL \| NZL \| NLD \| LTU \| LBN \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DNK \| DEU \| CZE \| CYP \| CAN \| BRA \| BGR \| BEL \| AUS	14
NCT06305962	Phase I	177Lu-RAD204	177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer	Recruiting	AUS	0
NCT03468426	Phase I	BI 836880 + Ezabenlimab	A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours	Completed	USA \| POL \| GBR \| FRA \| ESP \| DEU \| AUS	5
NCT04230954	Phase II	Cabozantinib + Pembrolizumab	Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer	Terminated	USA	0
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT04929041	Phase II	Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin	Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Recruiting	USA	0
NCT04739670	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)	Recruiting	AUS	0
NCT05570825	Phase II	Pembrolizumab + SX-682	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04685499	Phase II	OBP-301 + Pembrolizumab	Phase 2 Study of OBP-301 (Telomelysin) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease	Terminated	USA	0
NCT06275360	Phase II	Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)	Recruiting	USA	0
NCT04747054	Phase III	Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil	Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT)	Recruiting	FRA	0
NCT05980000	Phase II	Pembrolizumab + Ramucirumab Pembrolizumab	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)	Recruiting	USA	0
NCT05433116	Phase II	Lenvatinib + Pembrolizumab	Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC	Recruiting	DEU	0
NCT04047862	Phase I	BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab	Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors	Completed	USA \| NZL \| AUS	3
NCT02332668	Phase Ib/II	Pembrolizumab	A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)	Recruiting	USA \| SWE \| NLD \| ITA \| ISR \| GBR \| FRA \| DEU \| BRA	1
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT06492759	Phase II	Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab	High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer	Not yet recruiting	USA	0
NCT04856176	Phase II	Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim	A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy	Terminated	USA	0
NCT05642195	Phase Ib/II	H1299 cell lysate vaccine + Montanide ISA 51 + Nogapendekin alfa inbakicept H1299 cell lysate vaccine + Montanide ISA 51	Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	Suspended	USA	0
NCT05417321	Phase Ib/II	HB0036	A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors	Recruiting	USA	1
NCT04220866	Phase II	Pembrolizumab + Ulevostinag Pembrolizumab	Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)	Completed	USA \| NOR \| ISR \| GBR \| FRA \| ESP \| BRA \| AUT \| AUS	1
NCT04467723	Phase Ib/II	Atezolizumab + Pirfenidone	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	Recruiting	USA	0
NCT04049617	Phase Ib/II	Evixapodlin	Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors	Terminated	USA \| NZL	0
NCT02879162	Phase II	Durvalumab + Tremelimumab	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	Unknown status	CAN	0
NCT02494583	Phase III	Capecitabine Cisplatin + Fluorouracil Pembrolizumab	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	Completed		0
NCT03322540	Phase II	Pembrolizumab Epacadostat + Pembrolizumab	Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)	Completed	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GBR \| EST \| ESP \| DNK \| CHE \| CAN \| AUS	5
NCT03236935	Phase I	L-NMMA + Pembrolizumab	Phase Ib of L-NMMA and Pembrolizumab	Active, not recruiting	USA	0
NCT03233724	Phase Ib/II	Pembrolizumab	Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas	Terminated	USA	0
NCT04082364	Phase II	Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Capecitabine + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Margetuximab-cmkb + Retifanlimab Capecitabine + Margetuximab-cmkb + MGD013 + Oxaliplatin Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Margetuximab-cmkb + MGD013 + Oxaliplatin	Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)	Active, not recruiting	USA \| POL \| ITA \| GBR \| DEU	4
NCT02031458	Phase II	Atezolizumab	A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH	Completed	USA \| TUR \| SVN \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BGR \| BEL \| AUS	5
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT04432207	Phase I	IMU-201 Atezolizumab + IMU-201	A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Active, not recruiting	USA \| AUS	0
NCT05414032	Phase II	AZD2936	Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)	Recruiting	CAN	0
NCT04266730	Phase I	PANDA-VAC + Pembrolizumab + Poly ICLC	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	Not yet recruiting	USA	0
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT05171777	Phase II	Atezolizumab	A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer	Completed	USA \| POL \| LVA \| ITA \| FIN \| ESP \| CAN \| BRA \| ARG	3
NCT05814666	Phase II	Pembrolizumab Danvatirsen + Pembrolizumab	Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)	Recruiting	USA \| GBR	1
NCT05609578	Phase II	Adagrasib + Pembrolizumab	Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	Recruiting	USA \| POL \| ITA \| HUN \| GRC \| FRA \| ESP \| CHE \| BRA	5
NCT05210413	Phase Ib/II	Pazopanib + Spartalizumab	Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO)	Recruiting	FRA	0
NCT04262856	Phase II	AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)	Active, not recruiting	USA \| CAN \| AUS	4
NCT04596150	Phase II	CX-2009 CX-072 + CX-2009	Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer	Completed	USA \| ESP	1
NCT03937141	Phase II	MIW815 + Pembrolizumab	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	Terminated	USA	0
NCT06638931	Phase II	Nivolumab	Agnostic Therapy in Rare Solid Tumors (ANTARES)	Recruiting	BRA	0
NCT06667154	Phase II	Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy	Recruiting	BRA	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT05821777	Phase Ib/II	LB101	A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors	Recruiting	USA \| FRA	0
NCT04914897	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707	A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)	Terminated	USA \| POL \| ITA \| FRA \| ESP \| AUS \| ARG	4
NCT03921021	Phase II	OBP-301 + Pembrolizumab	Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	Completed	USA	0
NCT03991819	Phase I	Binimetinib + Pembrolizumab	Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer	Recruiting	CAN	0
NCT06543576	Phase Ib/II	Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab	External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer	Not yet recruiting	USA	0
NCT05859477	Phase II	Capecitabine + Nivolumab + Oxaliplatin	Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2)	Recruiting	USA	0
NCT04150562	Phase II	Avelumab + rhIL-15	Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma	Terminated	USA	0
NCT06346197	Phase III	Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Balstilimab + Botensilimab	Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME)	Not yet recruiting	FRA	0
NCT04622007	Phase II	Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib	Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)	Active, not recruiting	USA \| AUS	1
NCT05751798	Phase Ib/II	OSE-279	Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas	Recruiting	FRA \| BEL	0
NCT06692738	Phase III	AZD2936 + Carboplatin + Nab-paclitaxel AZD2936 + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| ARG	8
NCT06333951	Phase I	AMG193 + Pembrolizumab AMG193 + Carboplatin + Pembrolizumab + Pemetrexed Disodium AMG193 AMG193 + Sotorasib AMG193 + Carboplatin + Paclitaxel + Pembrolizumab	AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)	Recruiting	USA \| AUS	4
NCT06096844	Phase III	Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium	Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	Recruiting	USA	0
NCT06016920	Phase Ib/II	Pembrolizumab + VB10.16	Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma	Recruiting	POL \| NOR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE	0
NCT04969861	Phase II	NKTR-214 + Pembrolizumab Pembrolizumab	BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)	Terminated	USA \| ITA \| GRC \| AUT	0
NCT04128696	Phase III	Pembrolizumab GSK3359609 + Pembrolizumab	Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)	Terminated	USA \| ROU \| POL \| NOR \| NLD \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| AUS \| ARG	7
NCT05067283	Phase I	MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin	A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)	Recruiting	USA \| TUR \| POL \| NZL \| ITA \| ISR \| ESP \| DNK \| CHE \| CAN \| AUS	7
NCT06627647	Phase III	AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	9
NCT04249167	Phase I	Atezolizumab + Nab-paclitaxel	Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer	Withdrawn		0
NCT06103864	Phase III	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan Carboplatin + Gemcitabine + Pembrolizumab	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Recruiting	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS \| ARG	11
NCT04732494	Phase II	BGBA1217 + Tislelizumab Tislelizumab	AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma	Completed	FRA \| ESP	4
NCT05422794	Phase I	Nab-paclitaxel + Pembrolizumab + ZEN-3694	Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Recruiting	USA	0
NCT06635824	Phase III	Docetaxel GEN1046 + Pembrolizumab	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Recruiting	USA	3
NCT03896074	Phase II	Atezolizumab + Bevacizumab Atezolizumab	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)	Unknown status	ITA	0
NCT02574533	Phase I	Pembrolizumab FANG vaccine	Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma	Completed	USA	0
NCT05879822	Phase II	INCB099280	A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Active, not recruiting	TUR \| ROU \| NZL \| HUN \| GRC \| BRA	3
NCT06219174	Phase Ib/II	Eflornithine + Pembrolizumab	Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)	Recruiting	USA	0
NCT06623656	Phase II	Cemiplimab	Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	Not yet recruiting	USA	0
NCT04579757	Phase Ib/II	Surufatinib + Tislelizumab	Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	Active, not recruiting	USA	0
NCT03409614	Phase III	Cemiplimab + Ipilimumab Cemiplimab	Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer	Active, not recruiting	USA \| TUR \| SVK \| ROU \| POL \| LTU \| ITA \| IRL \| GRC \| FRA \| AUT	7
NCT06062420	Phase II	Dostarlimab-gxly Dostarlimab-gxly + EOS-448 + GSK6097608 Dostarlimab-gxly + GSK6097608 Dostarlimab-gxly + EOS-448	A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202	Recruiting	USA \| TUR \| ROU \| POL \| NOR \| ITA \| HUN \| GRC \| FRA \| FIN \| ESP \| DNK \| DEU \| CAN \| BRA \| ARG	4
NCT06342037	Phase II	Atezolizumab + Tiragolumab Ipilimumab + Tiragolumab Atezolizumab + Ipilimumab + Tiragolumab	NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)	Recruiting	NLD	0
NCT04434560	Phase II	Ipilimumab + Nivolumab	Neoadjuvant Immunotherapy in Brain Metastases	Terminated	USA	0
NCT03898180	Phase III	Lenvatinib + Pembrolizumab Pembrolizumab	Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)	Completed	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| AUS \| ARG	5
NCT05233696	Phase II	Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab	Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC	Withdrawn	USA	0
NCT05487235	Phase I	Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA \| POL \| NZL \| ESP \| CAN \| BRA \| AUS \| ARG	2
NCT05117242	Phase II	GEN1046 + Pembrolizumab GEN1046	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	1
NCT05093387	Phase I	Carboplatin + Pembrolizumab + SGT-53	SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer	Withdrawn	USA	0
NCT05144529	Phase II	Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab	A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)	Recruiting	USA	0
NCT05859217	Phase II	Atezolizumab + Cabozantinib	A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)	Not yet recruiting	USA	0
NCT05493566	Phase I	Aldesleukin + Pembrolizumab	Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05211895	Phase III	Durvalumab AB154 + Durvalumab	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)	Recruiting	USA \| TUR \| ROU \| POL \| NOR \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL	11
NCT04660344	Phase III	Atezolizumab	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)	Active, not recruiting	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| BRA \| BEL \| ARG	9
NCT04777994	Phase I	ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484	A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors	Recruiting	USA \| ISR \| FRA \| ESP	2
NCT04958811	Phase II	Atezolizumab + Bevacizumab + Tiragolumab	Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC	Recruiting	USA	0
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Terminated	USA \| GBR \| BEL \| AUS	1
NCT05332561	Phase II	Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab	Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)	Recruiting	DEU	0
NCT04675294	Phase II	Evorpacept + Pembrolizumab Pembrolizumab	Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Active, not recruiting	USA \| NLD \| GBR \| ESP \| CAN \| BEL \| AUS	2
NCT04294810	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| ESP \| DEU \| CHE \| BRA \| AUT \| AUS	10
NCT05681039	Phase II	Atezolizumab + Carboplatin + Tiragolumab Atezolizumab + Cisplatin + Tiragolumab Atezolizumab + Tiragolumab	Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).	Recruiting	USA	0
NCT04093167	Phase II	Pembrolizumab	Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC	Recruiting	USA \| CAN	0
NCT04795713	Phase I	MT-6402	Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1	Terminated	USA	0
NCT02681549	Phase II	Bevacizumab + Pembrolizumab	Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03511222	Phase I	Pembrolizumab + Vorolanib Nivolumab + Vorolanib	Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors	Terminated	USA	0
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| TUR \| ROU \| POL \| NZL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT06003621	Phase II	Atezolizumab + Tiragolumab	Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)	Recruiting	AUS	0
NCT06157151	Phase II	Pembrolizumab + PRGN-2009 Pembrolizumab	PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer	Recruiting	USA	0
NCT03407976	Phase Ib/II	Pembrolizumab + Rivoceranib	Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies	Terminated	USA	0
NCT03515629	Phase III	Cemiplimab + Ipilimumab Pembrolizumab	REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer	Terminated	USA \| LTU \| ITA	0
NCT05001347	Phase II	Uliledlimab	A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors	Completed	USA	0
NCT05669846	Phase II	Fecal microbiota + Pembrolizumab	Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC	Recruiting	USA	0
NCT02087423	Phase II	Durvalumab	A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)	Active, not recruiting	USA \| POL \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUT	6
NCT05920356	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Sotorasib	A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NLD \| LVA \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	13
NCT06211335	Phase I	Losartan + Pembrolizumab	Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma	Recruiting	USA	0
NCT03847519	Phase Ib/II	ADXS-503 + Pembrolizumab ADXS-503	Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer	Completed	USA	0
NCT03978689	Phase I	CUE-101 + Pembrolizumab CUE-101	A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma	Active, not recruiting	USA	0
NCT03425006	Phase II	Itacitinib + Pembrolizumab	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	Terminated	USA	0
NCT06047379	Phase Ib/II	NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Recruiting	USA	0
NCT04925986	Phase II	Pembrolizumab + Sitravatinib	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC	Terminated	USA	0
NCT05816252	Phase II	Osimertinib + SKB264 Carboplatin + SKB264 Carboplatin + Pembrolizumab + SKB264 Pembrolizumab + SKB264	A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	Recruiting	TUR \| ROU \| ESP	3
NCT03918499	Phase Ib/II	Cyclophosphamide + IRX-2 + Pembrolizumab	IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer	Completed	USA	0
NCT06579196	Phase Ib/II	Pembrolizumab + Trabedersen	Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1	Not yet recruiting	USA	0
NCT05323656	Phase II	Pembrolizumab Pembrolizumab + Setanaxib	A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT02880371	Phase Ib/II	ARRY-382 + Pembrolizumab	A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors	Terminated	USA	0
NCT06253611	Phase II	Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin EXL01 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin	First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS >=5 Metastatic Gastric Cancer (BIG)	Recruiting	FRA	0
NCT05142189	Phase I	BNT116 + Cemiplimab BNT116 + Docetaxel BNT116	Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)	Recruiting	USA \| TUR \| POL \| HUN \| GBR \| ESP \| DEU	0
NCT05877430	Phase Ib/II	CJRB-101 + Pembrolizumab	Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer	Recruiting	USA	1
NCT05879484	Phase Ib/II	DS-3201b + Pembrolizumab	Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS	Not yet recruiting	USA	0
NCT04958785	Phase II	Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel	Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)	Terminated	USA \| GBR \| AUS	3
NCT04738487	Phase III	Pembrolizumab MK-7684A	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	Active, not recruiting	USA \| TUR \| ROU \| HUN \| CAN \| BRA	17
NCT03679767	Phase II	Retifanlimab	A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)	Completed	USA \| ROU \| POL \| ITA \| HUN \| FRA \| ESP \| AUT	0
NCT06099418	Phase II	VB10.16 Atezolizumab + VB10.16	Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.	Withdrawn		0
NCT03371017	Phase III	Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine	A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)	Completed	USA \| TUR \| POL \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| DEU \| BRA \| ARG	16
NCT04060342	Phase Ib/II	GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel	GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma	Terminated	USA \| GBR	0
NCT02240238	Phase Ib/II	Gemcitabine + NC-6004	Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer	Completed	USA \| ROU \| POL \| ITA \| BGR	0
NCT05852691	Phase II	Nab-paclitaxel + RO7247669 Nab-paclitaxel + Pembrolizumab	A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Active, not recruiting	USA \| POL \| ITA \| ISR \| HUN \| ESP \| DNK \| DEU \| CZE \| BRA \| AUS \| ARG	6
NCT03809624	Phase II	INBRX-105 INBRX-105 + Pembrolizumab	Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB)	Terminated	USA	0
NCT02779751	Phase II	Abemaciclib + Pembrolizumab	A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer	Active, not recruiting	USA \| TUR \| ITA \| FRA \| ESP \| BEL	1
NCT04791839	Phase II	AB154 + Etrumadenant + Zimberelimab	Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04534205	Phase II	BNT113 + Pembrolizumab Pembrolizumab	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)	Recruiting	USA \| TUR \| SWE \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	5
NCT05172258	Phase II	Ipatasertib + Pembrolizumab Pembrolizumab	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	Recruiting	USA	0
NCT03971045	Phase II	Cyclophosphamide + Pembrolizumab	Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES)	Recruiting	ITA	0
NCT04341181	Phase II	Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)	Recruiting	DNK	0
NCT05899608	Phase III	Pembrolizumab Ivonescimab	Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients	Recruiting	USA \| CAN	0
NCT05533697	Phase Ib/II	mRNA-4359 + Pembrolizumab mRNA-4359	Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Recruiting	USA \| GBR \| ESP \| AUS	0
NCT03008018	Phase I	KA2507	Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours	Completed	USA	0
NCT06699212	Phase III	Cisplatin + Docetaxel + Fluorouracil + Pembrolizumab Carboplatin + Docetaxel + Fluorouracil + Pembrolizumab Pembrolizumab ASP-1929 + Pembrolizumab Cisplatin + Fluorouracil + Paclitaxel + Pembrolizumab Carboplatin + Fluorouracil + Paclitaxel + Pembrolizumab	A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases (ECLIPSE)	Recruiting	USA	0
NCT06256588	Phase III	Dostarlimab-gxly	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	7
NCT03563716	Phase II	Atezolizumab + Tiragolumab Atezolizumab	A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Active, not recruiting	USA \| FRA \| ESP	3
NCT03567720	Phase II	Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid	Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC	Active, not recruiting	USA \| AUS	0
NCT03520686	Phase III	Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.	Active, not recruiting	USA	0
NCT06238635	Phase II	Cobolimab + Dostarlimab-gxly Cobolimab	Dostarlimab and Cobolimab in Advanced Cervical Cancer	Recruiting	USA	0
NCT06203600	Phase II	Paclitaxel + Ramucirumab Nivolumab + Paclitaxel + Ramucirumab	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Recruiting	USA	0
NCT02352948	Phase III	Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)	Completed	USA \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BGR \| BEL \| AUS	9
NCT03891953	Phase I	DKY709 DKY709 + Spartalizumab	Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.	Active, not recruiting	USA \| ESP \| DEU	3
NCT05743270	Phase II	Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	USA \| POL \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE	0
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT05102214	Phase Ib/II	HLX301	HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors	Recruiting	AUS	0
NCT05060432	Phase Ib/II	EOS-448 + Pembrolizumab EOS-448 + EOS100850	Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| BEL	0
NCT05459129	Phase Ib/II	Atezolizumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab	A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)	Completed	USA \| ISR \| FRA \| AUS	1
NCT04796012	Phase Ib/II	Atezolizumab + Irinotecan + Temozolomide + Vincristine Sulfate	VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors	Recruiting	USA	0
NCT04798781	Phase II	Pembrolizumab + Telatinib	Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma	Active, not recruiting	USA	0
NCT06525220	Phase III	Pembrolizumab MCLA-158 + Pembrolizumab	A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer	Recruiting	USA \| ISR \| CAN \| AUS \| ARG	3

Profile Name	CD274 positive
Gene Variant Detail	CD274 positive (unknown)
Relevant Treatment Approaches	Atezolizumab Ipilimumab + Nivolumab Pembrolizumab

Molecular Profile Detail

Contact

Filtering

Sorting